Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer.

Linnaeus Therapeutics

Linnaeus Therapeutics, Inc. | 580 followers on LinkedIn. Privately held biotech developing drugs for cancer | Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics that target G protein-coupled receptors. The company was formed and launched in partnership with the UPstart incubator at the University of Pennsylvania’s Penn Center for Innovation (PCI).

COO at Linnaeus Therapeutics

Tina Garyantes

Executive Director of PCI Ventures

Michael Poisel

Patrick Mooney

Cofounder & CSO at Linnaeus Therapeutics

Christopher Natale, PhD

Linnaeus Therapeutics, Inc.

We've recently identified attempts to impersonate Linnaeus through fake letterhead and domain names. We take such matters very seriously and have taken action against these individuals.

Viewport Meta

IPhone / Mobile Compatible

WordPress

Yoast WordPress SEO Plugin

Yoast Plugins

Facebook Sharer

Yoast SEO Premium

Contact Form 7

Nikos Iatropoulos

Todd Ridky

Co-founder

Christopher Natale

Co-Founder & VP of Research

Private Northeastern US Companies (Top 10K)

University of Pennsylvania Alumni Founded Companies

New Jersey Companies With Fewer Than 1000 Employees (Top 10K)

Northeastern US Health Care Companies (Top 10K)

Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents that modulate cellular differentiation for the treatment of cancer and disorders of pigmentation.Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016 and is based upon discoveries from the Ridky lab at the University of Pennsylvania.

Venture Round - Linnaeus Therapeutics

Series C - Linnaeus Therapeutics

Kairos Ventures

Series B - Linnaeus Therapeutics

Series A - Linnaeus Therapeutics

Haddonfield

New Jersey

United States

North America

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the European Patent Office

Enantiomerically purified gper agonist for use in treating disease states and …

Cutaneous Melanoma Market is Predicted to Exhibit ...

Why Kairos Ventures Is Betting Big On ‘Omics’ To Power The Biotech Revolution

Diagnostic methods and compositions for treatment of cancer

Oncologic variations associated with cancer and methods of treatment

An orally bioavailable and highly specific agonist of the G protein-coupled estrogen receptor (GPER) that depletes c-Myc protein levels, showing antitumor activities in preclinical cancer models and being tested in clinical trials as a monotherapy and in combination with pembrolizumab.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 22, 2024 9:31 PM	1ec27697
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 22, 2024 9:31 PM	e05e5a6f
crunchbase trigger	general	Nov 22, 2024 9:31 PM	f2782c69
crunchbase profile	general	Nov 23, 2024 9:34 PM	e0823ff0
li profile	general	Nov 22, 2024 9:31 PM	330f3ebb
translate crunchbase fundingrounds	general	Nov 23, 2024 10:08 PM	769e23ca
peers	general	Nov 22, 2024 9:31 PM	b9a0ac21
news basic	general	Nov 22, 2024 9:31 PM	014d69ec
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

LINN

COM:LINNAEUSTX

Linnaeus Therapeutics